Abstract
The Network for Improving Quality of Care for Maternal, Newborn and Child Health (QCN) aims to work through learning, action, leadership and accountability. We aimed to evaluate the effectiveness of QCN in these four areas at the global level and in four QCN countries: Bangladesh, Ethiopia, Malawi and Uganda.
This mixed method evaluation comprised 2-4 iterative rounds of data collection between 2019-2022, involving stakeholder interviews, hospital observations, QCN members survey, and document review. Qualitative data was analysed using a coding framework developed from underlying theories on network effectiveness, behaviour change, and QCN proposed theory of change. Survey data capturing respondents’ perception of QCN was analysed with descriptive statistics.
The QCN global level, led by the WHO secretariat, was effective in bringing together network countries’ governments and global actors via providing online and in-person platforms for communication and learning. In-country, various interventions were delivered in ‘learning districts’, however often separately by different partners in different locations, and disrupted by the pandemic. Governance structures for quality of care were set-up, some preceding QCN, and were found to be stronger and better (though often externally) resourced at national than local levels. Awareness of operational plans and network activities was lower at local than national levels but increased from 2019 to 2022. Capacity building efforts were implemented – yet often dependent on implementing partners and donors. QCN stakeholders agreed 15 core monitoring indicators though data collection was challenging, especially for indicators requiring new or parallel systems including those on experience of care. Accountability through community engagement, scorecards, and ombudsmen was encouraged but these initiatives remained nascent in 2022.
Global and national leadership elements of QCN have been most effective to date, with action, learning and accountability more challenging, partner or donor dependent, remaining to be scaled-up, and pandemic-disrupted.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was funded by the Medical Research Council (MRC) Health Systems Research Initiative 5th call via grant MR/S013466/1 to TC at UCL Institute for Global Health, United Kingdom, YS and JS at Johns Hopkins University, United States of America, KA and AK at Diabetic Association of Bangladesh Perinatal Care Project, Bangladesh, CM at Parent and Child Health Initiative, Malawi, GS at Makerere University School of Public Health, Uganda, and ME at University of Oxford, United Kingdom and by the Bill & Melinda Gates foundation via grant INV-007644 to TM at LSHTM, United Kingdom. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All interviews, observations and surveys were conducted after obtaining informed consent. Ethical approval was received from University College London Research Ethics Committee (ref: 3433/003) BADAS Ethical Review Committee (ref: BADAS-ERC/EC/19/00274), Ethiopian Public Health Institute Institutional Review Board (ref: EPHI-IRB-240-2020), National Health Sciences Research Committee in Malawi (ref: 19/03/2264) and Makerere University Institutional Review Board (ref: Protocol 869).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data is derived from qualitative interviews, most with stakeholders where only one individual holds a position, either within federal or state government, facilities, or NGOs. Every care has been taken to ensure anonymity of the data in the submitted manuscript but the authors from all 4 countries feel strongly that making data freely available would jeopardise the conditions of informed consent. We therefore request to be exempt from the requirement to make data available but have uploaded a detailed methods document (S2_Text). Thank you for your consideration.
